Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.
Working on the premise that too much of a good thing can be a killer, the scientists have advanced previous researchers methods of manipulating an enzyme that is key to how influenza replicates and spreads.
Their new compounds will lead to a new generation of anti-influenza drugs that the virus strains cant adapt to, and resist, as easily as they do Tamiful. Its an anti-influenza drug that is becoming less effective against the constantly mutating flu virus.
These increasingly less adequate anti-influenza drugs are currently doctors best weapons against influenza. They helped the world beat H1N1, swine flu, into submission four years ago.
The journal Science Express has just published online the scientists study, revealing how to use their newly discovered compounds to interrupt the enzyme neuraminidases facilitation of influenzas spread.
Tamiful and another anti-influenza drug, Relenza, focus on interrupting neuraminidases ability to help influenza detach from an infected cells surface by digesting sialic acid, a sugar on the surface of the cell. The flu virus uses the same sugar to stick to the cell while invading it. Once attached, influenza can invade the cell and replicate.
This is where the newly discovered compounds come to the still-healthy cells rescue. They clog up neuraminidase, stopping the enzyme from dissolving the sialic acid, which prevents the virus from escaping the infected cell and spreading.
The new compounds are also more effective because theyre water-soluble. They reach the patients throat where the flu virus is replicating after being taken orally, says Niikura, a Faculty of Health Sciences associate professor.
Influenza develops resistance to Replenza less frequently, but its not the drug of choice like Tamiful because its not water-soluble and has to be taken as a nasal spray.
Our new compounds are structurally more similar to sialic acid than Tamiful. We expect this closer match will make it much more difficult for influenza to adapt to new drugs.
Ultimately, the new compounds will buy scientists more time to develop new vaccines for emerging strains of influenza that are resistant to existing vaccines.
Source: Simon Fraser University
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.